Magenta Therapeutics, Inc. (NASDAQ:MGTA) Short Interest Update

Magenta Therapeutics, Inc. (NASDAQ:MGTAGet Rating) was the target of a significant decrease in short interest in August. As of August 31st, there was short interest totalling 413,500 shares, a decrease of 14.5% from the August 15th total of 483,800 shares. Approximately 1.1% of the company’s stock are short sold. Based on an average trading volume of 245,000 shares, the short-interest ratio is currently 1.7 days.

Magenta Therapeutics Stock Down 3.4 %

MGTA stock opened at $1.68 on Monday. Magenta Therapeutics has a twelve month low of $0.92 and a twelve month high of $8.49. The stock’s 50 day moving average is $1.78 and its 200-day moving average is $1.85. The firm has a market capitalization of $98.94 million, a PE ratio of -1.28 and a beta of 2.09.

Magenta Therapeutics (NASDAQ:MGTAGet Rating) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.08. On average, equities research analysts anticipate that Magenta Therapeutics will post -1.26 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, The Goldman Sachs Group lowered Magenta Therapeutics from a “buy” rating to a “neutral” rating and set a $2.00 target price on the stock. in a report on Wednesday, August 24th.

Institutional Trading of Magenta Therapeutics

Hedge funds have recently bought and sold shares of the business. Acadian Asset Management LLC bought a new stake in Magenta Therapeutics during the fourth quarter worth $29,000. BNP Paribas Arbitrage SA increased its position in Magenta Therapeutics by 496.9% in the second quarter. BNP Paribas Arbitrage SA now owns 27,834 shares of the company’s stock worth $33,000 after buying an additional 23,171 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in Magenta Therapeutics in the fourth quarter worth $127,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Magenta Therapeutics in the second quarter worth $40,000. Finally, Walleye Capital LLC increased its position in Magenta Therapeutics by 47.7% in the first quarter. Walleye Capital LLC now owns 41,341 shares of the company’s stock worth $120,000 after buying an additional 13,356 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors.

Magenta Therapeutics Company Profile

(Get Rating)

Magenta Therapeutics, Inc, a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD45-antibody drug conjugate that targets HSCs and immune cells, which is in investigational new drug application enabling studies for potential use as a single-agent in autoimmune diseases and hematology-oncology transplants; and MGTA-145 that is in Phase II clinical trial for use in autologous and allogeneic transplants.

Featured Articles

Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.